Marlio Charles Mosseri Buys 17,000 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) major shareholder Marlio Charles Mosseri purchased 17,000 shares of the business’s stock in a transaction on Friday, December 13th. The shares were bought at an average price of $4.70 per share, for a total transaction of $79,900.00. Following the acquisition, the insider now owns 2,612,000 shares in the company, valued at $12,276,400. This trade represents a 0.66 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Nuvectis Pharma Stock Performance

Shares of Nuvectis Pharma stock opened at $5.11 on Wednesday. The business has a 50-day simple moving average of $6.52 and a 200-day simple moving average of $6.55. Nuvectis Pharma, Inc. has a one year low of $4.52 and a one year high of $12.10. The company has a market cap of $98.73 million, a PE ratio of -4.41 and a beta of 0.20.

Nuvectis Pharma (NASDAQ:NVCT) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.01. During the same quarter last year, the firm posted ($0.37) EPS. On average, sell-side analysts predict that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nuvectis Pharma

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in shares of Nuvectis Pharma by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 298,800 shares of the company’s stock valued at $2,450,000 after acquiring an additional 4,517 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Nuvectis Pharma by 20.7% in the second quarter. Renaissance Technologies LLC now owns 74,500 shares of the company’s stock valued at $472,000 after purchasing an additional 12,800 shares in the last quarter. Nations Financial Group Inc. IA ADV purchased a new position in Nuvectis Pharma in the third quarter valued at approximately $63,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Nuvectis Pharma during the second quarter worth approximately $58,000. Finally, Geode Capital Management LLC lifted its position in shares of Nuvectis Pharma by 49.8% during the 3rd quarter. Geode Capital Management LLC now owns 79,716 shares of the company’s stock worth $501,000 after buying an additional 26,489 shares during the last quarter. Hedge funds and other institutional investors own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.